B Cell Lymphoma
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
Conference Coverage
Lenalidomide maintenance improves MCL survival after ASCT
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.
Conference Coverage
Checkmate 436: Two-drug combo is ‘promising’ for PMBCL
SAN DIEGO – The early results suggest a high overall response to the drug combination.
News
Survivors of childhood Hodgkin lymphoma face 14-fold risk of second cancers
The findings highlight the need to screen high-risk subgroups of cancer survivors.
Conference Coverage
ECHELON-2: BV-CHP boosts survival in PTCL
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
CHMP recommends BV+AVD for Hodgkin lymphoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Lymphodepletion improves efficacy of CAR T cells in HL
SAN DIEGO—A phase 1 study suggests lymphodepletion can improve the efficacy of CD30-directed chimeric antigen receptor (CAR) T-cell therapy in...
News
Mutation confers resistance to venetoclax in CLL
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients...